Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Immopharma from Erpe-Mere, company number BE0427622025, closed financial year 2025 with a result of € 2,096 after tax. For that financial year Immopharma recorded a gross margin of € 9,655 and equity of € 222,692. Compared with financial year 2024, the result moved from € -10,643 to € 2,096. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 31, 2026.
€ 222,692
▲ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2,096
▲ still € 10,643 loss in 2024
Profit after tax over the fiscal year.
€ 16,928
▲ 282% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 160,692.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 86
▼ 37% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 152
▲ € 152 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -6,788 | € -7,621 | € -395 | € 9,655 | ▲ € 10,050 |
| Profit after taxes | € -14,450 | € -18,830 | € -10,643 | € 2,096 | ▲ € 12,739 |
| Equity | € 250,069 | € 231,239 | € 220,596 | € 222,692 | ▲ 1% |
| Total debts | € 120,784 | € 43,377 | € 38,611 | € 45,343 | ▲ 17% |
| Cash | € 101,805 | € 13,214 | € 4,432 | € 16,928 | ▲ 282% |
| Land & buildings | € 266,857 | € 260,452 | € 254,334 | € 250,631 | ▼ 1% |
| Retained profit | € 188,069 | € 169,239 | € 158,596 | € 160,692 | ▲ 1% |
| Balance sheet total | € 370,854 | € 274,616 | € 259,206 | € 268,035 | ▲ 3% |
Key figures of Immopharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to Immopharma?
What happened at Immopharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2,096. Source: NBB ↗
- New establishment in Erpe-Mere. KBO
- MARCEL DE VULDER became a director. NBB
- MONIQUE VAN EETVELDE became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 14,450 loss in 2022 to € 2,096 profit in 2025.
Paid € 514 in corporate taxes since 2022.
Best year ever: 2025, with € 2,096 profit.
Management
Behind Immopharma are MARCEL DE VULDER and MONIQUE VAN EETVELDE.
Directors
According to the 2025 annual accounts
MARCEL DE VULDER
Managing director
since 1993
MONIQUE VAN EETVELDE
Director
since 1993
Establishments
Establishment units
Physical locations of this company
Sint-Annastraat 4
9420 Erpe-Mere
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0427.622.025
- VAT number
- BE 0427.622.025
- Registered office
- Sint-Annastraat 4, 9420 Erpe-Mere
- Names & denominations
- Immopharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 November 1984
- Peppol
- Active · Active since 14 Jan 2026
- Activities · NACE
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Verhuur en exploitatie van terreinen